NASDAQ:TNXP - Tonix Pharmaceuticals Stock Price, News & Analysis

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

Tonix Pharmaceuticals shares reverse split on the morning of Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) announced its quarterly earnings data on Monday, August, 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.96) by $0.01. View Tonix Pharmaceuticals' Earnings History.

Tonix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Tonix Pharmaceuticals.

1 brokerages have issued 1-year price targets for Tonix Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Tonix Pharmaceuticals' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 759.1% from the stock's current price. View Analyst Price Targets for Tonix Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tonix Pharmaceuticals.

Media coverage about TNXP stock has been trending negative recently, InfoTrie reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tonix Pharmaceuticals earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Tonix Pharmaceuticals.

Tonix Pharmaceuticals saw a decrease in short interest in the month of July. As of July 31st, there was short interest totalling 471,300 shares, a decrease of 45.5% from the June 30th total of 864,500 shares. Based on an average trading volume of 555,700 shares, the days-to-cover ratio is presently 0.8 days. Currently, 20.3% of the shares of the company are sold short. View Tonix Pharmaceuticals' Current Options Chain.

Some companies that are related to Tonix Pharmaceuticals include AzurRx BioPharma (AZRX), Sienna Biopharmaceuticals (SNNA), Acerus Pharmaceuticals (ASPCF), KemPharm (KMPH), Aerpio Pharmaceuticals (ARPO), Sernova (SEOVF), Citius Pharmaceuticals (CTXR), Provectus Biopharmaceuticals (PVCT), Aytu Bioscience (AYTU), BIOLINERX LTD/S (BLRX), Acerus Pharmaceuticals (TRLPF), Addex Therapeutics (ADDXF), ProPhase Labs (PRPH), RegeneRx Biopharmaceuticals (RGRX) and Ceapro (CRPOF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Rite Aid (RAD), Novavax (NVAX), SCYNEXIS (SCYX), Synthetic Biologics (SYN), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Nektar Therapeutics (NKTR) and Rigel Pharmaceuticals (RIGL).

Tonix Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.55%), Acadian Asset Management LLC (0.43%) and A.R.T. Advisors LLC (0.20%). Company insiders that own Tonix Pharmaceuticals stock include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals.

TNXP stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Acadian Asset Management LLC and A.R.T. Advisors LLC. Company insiders that have bought Tonix Pharmaceuticals stock in the last two years include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Insider Buying and Selling for Tonix Pharmaceuticals.

Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TNXP stock can currently be purchased for approximately $0.4656.

Tonix Pharmaceuticals has a market capitalization of $7.15 million. The company earns $-26,090,000.00 in net income (profit) each year or ($26.81) on an earnings per share basis. Tonix Pharmaceuticals employs 12 workers across the globe.View Additional Information About Tonix Pharmaceuticals.

The official website for Tonix Pharmaceuticals is http://www.tonixpharma.com/.

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]